March 01, 2018
Valeant Pharmaceuticals International Inc. on Wednesday said it will pay more than $58 million to end pay-for-delay litigation in Massachusetts federal court alleging subsidiary Medicis Pharmaceutical Corp. illegally kept a generic for the acne medication Solodyn off the market.
February 13, 2018
The First Circuit on Monday denied an attempt by Valeant Pharmaceuticals subsidiary Medicis Pharmaceutical Corp. to stall a March trial slated to decide whether the company paid generic-drug makers to stay out of the market for acne medication Solodyn.
January 25, 2018
A Massachusetts federal judge on Thursday shot down acne-drug maker Medicis' attempt to escape allegations it participated in a pay-for-delay scheme to keep competing generics out of the market, saying a jury must decide numerous disputes of fact in the case.
January 02, 2018
Generic-drug makers Lupin Ltd. and Sandoz Inc. settled with Walgreen Co., CVS Pharmacy Inc., Rite Aid Corp. and other retailers over allegations in Massachusetts federal court that the manufacturers had accepted payments from Medicis Pharmaceutical Corp. to stay out of the market for acne medication Solodyn.
December 11, 2017
Walgreen Co., CVS Pharmacy Inc., Rite Aid Corp. and other retailers alleging Medicis Pharmaceutical Corp. paid generic-drug makers to stay out of the market for acne medication Solodyn urged a Massachusetts federal court Monday to reject Medicis' efforts to nix some of their claims.
November 22, 2017
Medicis Pharmaceutical Corp. and two classes of Solodyn buyers have each asked a Massachusetts federal court for quick wins to end the buyers' pay-for-delay suit accusing Medicis of paying generic-drug makers to stay off the market for the acne medication, with the parties fighting over how much competition exists.
October 16, 2017
End-payor and direct purchasers' bids for class certification were granted in Massachusetts federal court Monday in the pay-for-delay litigation against drugmakers Medicis Pharmaceutical Corp. and Impax Laboratories Inc. over the generic version of Medicis' acne medication Solodyn.
April 04, 2017
Sandoz Inc. and Lupin Ltd. have agreed to pay a combined $6.7 million to exit multidistrict litigation accusing them of striking a deal with a Valeant Pharmaceuticals Corp. unit to delay launching their generic versions of the acne medication Solodyn, according to a pair of proposed deals Tuesday.
August 14, 2015
A Massachusetts federal judge on Friday pared down multidistrict litigation accusing Medicis Pharmaceutical Corp. of paying off several generic drugmakers to delay launching their own versions of acne medication Solodyn, but allowed the core pay-for-delay allegations to go forward.